Archived: 11th Winter Conference
on Medicinal & Bioorganic Chemistry

January 20th - 24th 2013

Steamboat Springs Resort, Colorado


Sunday, January 20th 2013

Innovations in Drug Candidate Development

Program Chair: Trevor Laird, Scientific Update

Dr Trevor Laird Scientific Update

An Overview of Drug Candidate Development: Industrial Case Studies

Dr Carl Busacca Boehringer-Ingelheim

Development of a Manufacturing Route for the HCV Protease Inhibitor Faldaprevir

Dr John Ragan Pfizer

Strategies for Chirality Control on Multi-Kilogram Scale: Development of an Enantioselctive Synthesis of Filibuvir

Dr Diane Carrera Genetech

Early Process Research: Developing a Synthetic Strategy for PI3kd Inhibitors

Monday, January 21st 2013

Cancer Cell Metabolism and Opportunities for Therapeutic Intervention

Program Chair: Tim Burkholder, Eli Lilly & Co

Dr Sandaruwan Geeganage Eli Lilly and Company

Targeting Metabolic Reprogramming for Cancer

Dr Richard Cerione Cornell University

New Strategies for Impacting Glutamine Metabolism in Cancer Cells

Dr Matthew Boxer NIH

Pyruvate Kinase M2 Activators Induce Tetramerization and Reduce Tumor Size in Mouse Xenograft Models

Dr Janeta Popovici-Muller Agios Pharmaceuticals

Discovery and Characterization of Mutant IDH Inhibitors for the Treatment of Cancer

Dr Ken Bair Forma Therapeutics

Structure-based Identification of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors

Dr Peter Dragovich Genentech

Design of Optimized Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors

Neglected Infectious Diseases and Parasitic Infections

Program Chair: Richard Lee & Kip Guy, St Judes Children Research Hospital

Dr Bryan Yeung Novartis

The Discovery, Optimisation, and Mode of Action of Spiroindolone Antimalarials

Dr David Wilson GlaxoSmithKline

The Discovery and Optimization of Novel Anti-Malarial Agents Derived from Phenotypic Screening

Professor Courtney Aldrich University of Minnesota

Rational Design of Antibiotics for Tuberculosis that Target Biotin Metabolism

Professor Marvin Miller University of Notre Dame

Syntheses and Evaluation of New Anti-tuberculosis Agents Inspired by Studies of Mycobacterial Iron Assimilation

Tuesday, January 22nd 2013

Academic Session | Indiana University

Program Chair: Mike VanNieuwenhze, Indiana University

Professor Nikki Pohl Indiana University

Challenges in Glycan Synthesis

Professor Silas Cook Indiana University

The Quest for Affordable, Fully Synthetic Artemisinin

Professor Richard DiMarchi Indiana University

Chemical Biotechnology Applied to Endocrine Hormones

Professor Erin Carlson Indiana University

Chemoselective Enrichment for Natural Products Discovery

Professor Charles Dann Indiana University

Structural Insights into Targeted Drug Delivery via the Human Folate Receptors

Frontiers in Synthesis

Program Chair: Victor Snieckus, Queen’s University

Professor Paul Chirik Princeton University

Base Metal Catalysis for Organic Synthesis

Dr Scott Gilbertson University of Houston

Inhibitors of 5-HT2CR Protein:Protein Interactions for Stimulant Pharmacotherapy

Dr Paul Richardson Pfizer Worldwide R&D

Facilitation of Scale-Up of Novel Oncology Candidates through Early Route Optimisation – Risk and Rewards

Professor Janis Louie University of Utah

Advances in Ni- and Fe-Catalyzed Cycloaddition Chemistry

Wednesday, January 23rd 2013

New Frontiers in Medicinal Chemistry

Program Chair: Philippe Nantermet, Merck Research Laboratories

Dr Matt Hayward Pfizer

Covalent Inhibitors in Drug Design

Dr Steve Colletti Merck

Recent Advances in siRNA Delivery

Dr Antonia Stepan Pfizer

The Impact of Oxetane and Bicyclo[1.1.1]pentane Motifs on Biopharmaceutical Properties

Dr Colin Tice Vitae Pharmaceuticals

Drug Discovery and Optimization using Computer Generated Molecules with Predicted Potencies

Dr Serge Boulet Eli Lilly & Company

Phenotypic Drug Discovery of Novel Anti-Angiogenics

Open Session

Program Chair: Matt Hayward, Pfizer

Dr Ed Olhava Epizyme

Studies Leading to the Clinical Candidate EPZ-5676, a DOT1L Inhibitor for the Treatment of MLL-rearranged Leukemia

Dr Jamie Tuttle Pfizer

Discovery of a Series of Brain-Penetrant Kynurenine Aminotransferase II Inhibitors for the Treatment of Schizophrenia

Dr Rolf Wagner Abbott

Discovery of HCV Polymerase Inhibitors ABT-333 and ABT-072: Components of an IFN-sparing Drug Regimen

Dr Aaron Beeler University of Boston

Development and Application of a Highly Selective Histone Deacetylase 8 Inhibitor


Program Chair: Dr Philippe Nantermet, Merck

Dr. Peter Mueller CSO & Executive VP, Global Research & Development, Vertex Pharmaceuticals, USA

Imagine: Pharma Be Fractal

Thursday, January 24th 2013

Emerging Therapies for Hepatitis C

Program Chair: John A. McCauley, Merck Research Laboratories

Dr Omar Lopez BMS

Discovery of HCV NS5A Replication Complex Inhibitors

Dr Will Watkins Gilead

Optimization of HCV NS5B Thumb Site II Inhibitors for Use in Interferon-Free Regimens

Dr Andrew Woodhead Astex

Discovery of a Novel Allosteric Mechanism for the Regulation of HCV NS3 Protein using Fragment Screening and Structure-Based Design

Dr Deqiang Niu Celgene

The Discovery of a Potent and Selective Irreversible HCV Protease Inhibitor

Treatment of Liquid Disorders: Metabolic Syndrome and Beyond

Program Chair: Lance Pfeifer, Eli Lilly & Co

Dr Jason Elliott Novartis

DGAT1 Inhibitors for Suppression of Postprandial Triglycerides

Dr Amjad Ali Merck Research Laboratories

The Discovery and Development of Anacetrapib, a Potent and Orally Active CETP Inhibitor

Dr Jon Seiders BMS

The Discovery and Optimization of a Novel Series of LPA Receptor Antagonists with Efficacy in Multiple Mouse Models of Fibrosis

Dr Michael Vazquez Pfizer

Development of a Potent, Selective, and Orally Bioavailable mPGES-1 Inhibitor based on a Benzoxazole Template for the Treatment of Osteoarthritis Pain and Inflammation

Media Sponsors